arrow
J

Javier Martínez-Picado

irsicaixa
H指数:73
被引数:2.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

First-line dolutegravir/lamivudine in HIV-1 infection: lymph node penetration and reservoir decline in a randomized open-label clinical trial

HIV-1感染中一线多替拉韦/拉米夫定治疗:一项随机开放标签临床试验中的淋巴结渗透和病毒库下降

2026-10-020
OA
Humanized FLT3 mice display enhanced tissue engraftment and support HIV-1 persistence and rebound

人源化FLT3小鼠表现出增强的组织植入,并支持HIV-1的持续存在和反弹

2026-09-010
PRE
Long-term HIV-1 remission achieved through allogeneic haematopoietic stem cell transplant from a CCR5Δ32/Δ32 sibling donor

通过CCR5Δ32/Δ32同胞供体异基因造血干细胞移植实现长期HIV-1缓解

2026-04-130
OAAI
Immune and senescence profiles associated with non-AIDS-defining cancer risk in people with HIV: a case-cohort study

与HIV感染者非艾滋病定义性癌症风险相关的免疫和衰老特征:一项病例-队列研究

2025-10-210
OAAI
Unveiling altered CD8 T-cell metabolism and homeostatic proliferation behind a low CD4/CD8 ratio in ART-suppressed HIV individuals with normal CD4 recovery

揭示ART抑制的HIV感染者中正常CD4恢复背景下低CD4/CD8比率背后的CD8 T细胞代谢异常和稳态增殖

2025-09-080
OA
The imperative for increased investment for an HIV cure

加大投资以寻求艾滋病治愈的必要性

2025-07-220
PRE
Time to HIV viral rebound and frequency of post-treatment control after analytical interruption of antiretroviral therapy: an individual data-based meta-analysis of 24 prospective studies

抗逆转录病毒治疗分析性中断后,HIV病毒反弹时间和治疗后控制频率:一项基于24项前瞻性研究的个体数据meta分析

2025-01-212
OA
Impact of Dolutegravir Plus Lamivudine as First-line Antiretroviral Treatment on the Human Immunodeficiency Virus Type 1 Reservoir and Inflammatory Markers in Peripheral Blood

度鲁特韦联合拉米夫定一线抗逆转录病毒治疗对外周血人类免疫缺陷病病毒1型储库和炎症标志物的影响

2024-10-280
PRE
Sustained HIV remission after allogeneic hematopoietic stem cell transplantation with wild-type CCR5 donor cells
2024-09-024
PRE
Sustained aviremia despite anti-retroviral therapy non-adherence in male children after in utero HIV transmission
2024-06-063
OAAI
Preclinical development of humanized monoclonal antibodies against CD169 as a broad antiviral therapeutic strategy

抗CD169人源化单克隆抗体的临床前开发作为广泛的抗病毒治疗策略

2024-06-010
OAAI
Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs

Auto-abs中和I型干扰素患者的疫苗突破性低氧新型冠状病毒肺炎肺炎

2023-12-2243
OAAI